RVL Pharmaceuticals, Inc. is a new operating subsidiary of Osmotica Pharmaceuticals plc (Nasdaq: OSMT), and was created for the purpose of bringing Upneeq® (oxymetazoline hydrochloride ophthalmic solution), 0.1% to market. RVL Pharmaceuticals, Inc. is dedicated to developing unique partnerships with customers, as well as making Upneeq® available exclusively through our fully-owned and integrated pharmacy. Osmotica Pharmaceuticals plc is a fully integrated biopharmaceutical company focused on the development and commercialization of specialty products that target markets with underserved patient populations.